CODEXIS, INC.CDXSEarnings & Financial Report
Nasdaq · Health Care · Industrial Organic Chemicals
Codexis, Inc. is a protein engineering company that develops enzymes for pharmaceutical, food and medical applications.
CDXS Q4 FY2025 Key Financial Metrics
Revenue
$38.9M
Gross Profit
$36.9M
Operating Profit
$10.6M
Net Profit
$9.6M
Gross Margin
94.8%
Operating Margin
27.1%
Net Margin
24.7%
YoY Growth
81.3%
EPS
$0.13
CODEXIS, INC. Q4 FY2025 Financial Summary
CODEXIS, INC. reported revenue of $38.9M (up 81.3% YoY) for Q4 FY2025, with a net profit of $9.6M (up 192.5% YoY) (24.7% margin). Cost of goods sold was $2.0M, operating expenses totaled $26.3M.
Key Financial Metrics
| Total Revenue | $38.9M |
|---|---|
| Net Profit | $9.6M |
| Gross Margin | 94.8% |
| Operating Margin | 27.1% |
| Report Period | Q4 FY2025 |
CODEXIS, INC. Annual Revenue by Year
CODEXIS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $70.4M).
CODEXIS, INC. Quarterly Revenue & Net Profit History
CODEXIS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $38.9M | +81.3% | $9.6M | 24.7% |
| Q3 FY2025 | $8.6M | -33.0% | $-19.6M | -228.1% |
| Q2 FY2025 | $15.3M | +92.1% | $-13.3M | -86.6% |
| Q1 FY2025 | $7.5M | -55.8% | $-20.7M | -274.3% |
| Q4 FY2024 | $21.5M | -19.2% | $-10.4M | -48.4% |
| Q3 FY2024 | $12.8M | +38.3% | $-20.6M | -160.8% |
| Q2 FY2024 | $8.0M | -62.6% | $-22.8M | -285.2% |
| Q1 FY2024 | $17.1M | +31.5% | $-11.5M | -67.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.1M | $8.0M | $12.8M | $21.5M | $7.5M | $15.3M | $8.6M | $38.9M |
| YoY Growth | 31.5% | -62.6% | 38.3% | -19.2% | -55.8% | 92.1% | -33.0% | 81.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $149.6M | $132.0M | $148.2M | $149.0M | $128.9M | $138.2M | $124.0M | $147.8M |
| Liabilities | $70.3M | $70.6M | $74.8M | $82.1M | $79.3M | $82.6M | $85.4M | $97.3M |
| Equity | $79.3M | $61.4M | $73.4M | $66.9M | $49.6M | $55.6M | $38.5M | $50.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-7.8M | $-12.2M | $-13.0M | $-16.5M | $-13.8M | $-18.0M | $-7.7M | $20.1M |